Niagen Bioscience posted Q2 net income of USD 963,000, down 73.32% year over year; net sales fell 4% to USD 29.79 million.
Consumer Products net sales rose 6% to USD 24.16 million, while Ingredients net sales dropped 29% to USD 5.39 million.
Sales and marketing expense climbed to USD 10.13 million from USD 8.21 million, lifting the spend rate to 34% of net sales from 26.4%.
Product and pipeline updates
Launched the Niagen Plus telehealth platform in May, expanding clinician-directed access to at-home injection kits for eligible U.S. patients.
Introduced rare-disease candidate NB4168 for Ataxia-Telangiectasia in July; FDA granted Rare Pediatric Disease designation, EMA granted Orphan Medicinal Product Designation.
NAGE•
